RNase protection assay of transcripts in IL-2–activated and –propagated lymphocytes derived from patients with type 3 deficiency in cellular cytotoxicity.

RNA isolates of IL-2–propagated lymphocytes (LAK + 7 day IL-2 culture) from 4 patients with type 3 cytotoxic deficiency (HLH-1, HLH-2, HLH-3, HLH-4) were subjected to the RiboQuant RNase protection assay. Probes for defined transcripts are given in panels A and B (first lane). Horizontal lines link shifted mRNA bands (A) and the free probe (first lane, B). Control transcripts (L32 and GAPDH) are positive in healthy controls and in type 3–deficient patients. Arrowheads mark minor differences in the relative density of the granzyme 3–specific bands in HLH-1 and HLH-2.